title: Antihyperlipidemic activity of adenosine triphosphate in rabbits fed a high-fat diet and hyperlipidemic patients.
abstract: Context Recently, adenosine triphosphate (ATP) was occasionally found to decrease the triglyceride (TG) levels in several hyperlipidemic patients in our clinical practice. Objective The study investigates the anti-hyperlipidemic effects of ATP in a high-fat fed rabbit model and hyperlipidemic patients. Materials and methods Twenty-four rabbits were randomly divided into three groups of eight animals each as follows: normal diet, high-fat diet and high-fat diet + ATP group. ATP supplementation (40 mg/day) was started at the 20th day and lasted for 10 days. Serum concentrations of total cholesterol (TC), TG, LDL-C, HDL-C were measured on the 20th day and 30th day. Heart, liver and aorta were subjected histopathological examination. Twenty outpatients diagnosed primary hyperlipidemia took ATP at a dose of 60 mg twice a day for 1 week. Results Feeding rabbits with a high-fat diet resulted in a significant elevation of lipid parameters including TC, TG, LDL-C, VLDL-C compared to the normal diet group (p < 0.01). ATP treatment significantly decreased serum TG level (p < 0.01), whilst other parameters remained statistically unaltered. Meanwhile, ATP significantly reduced the thickness of fat layer in cardiac epicardium (p < 0.05) and pathological gradation of ballooning degeneration in hepatocytes (p < 0.05). After taking ATP for 1 week, hyperlipidemia patients exhibited a significant decrease of TG (p < 0.01), but other lipid parameters had no significant change. Discussion and conclusion The study indicates that ATP selectively decreases serum TG levels in high-fat diet rabbits and hyperlipidemic patients. Therefore, ATP supplementation may provide an effective approach to control TG level.
authors.affiliation: a Department of Pathology , Hebei Medical University , Shijiazhuang , P.R. China ;
authors.forename: Lianshan
authors.initials: L
authors.lastname: Zhang
authors.affiliation: b Hebei Xinglong Institute of Pharmacological and Medical Science , Shijiazhuang , P.R. China.
authors.forename: Libin
authors.initials: L
authors.lastname: Liang
authors.affiliation: b Hebei Xinglong Institute of Pharmacological and Medical Science , Shijiazhuang , P.R. China.
authors.forename: Tong
authors.initials: T
authors.lastname: Tong
authors.affiliation: b Hebei Xinglong Institute of Pharmacological and Medical Science , Shijiazhuang , P.R. China.
authors.forename: Yuguo
authors.initials: Y
authors.lastname: Qin
authors.affiliation: b Hebei Xinglong Institute of Pharmacological and Medical Science , Shijiazhuang , P.R. China.
authors.forename: Yanping
authors.initials: Y
authors.lastname: Xu
authors.affiliation: b Hebei Xinglong Institute of Pharmacological and Medical Science , Shijiazhuang , P.R. China.
authors.forename: Xinglong
authors.initials: X
authors.lastname: Tong
mesh_terms: D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000818:Animals; D015415:Biomarkers / Q000097:blood; D059305:Diet, High-Fat; D004195:Disease Models, Animal; D015536:Down-Regulation; D005260:Female; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D011817:Rabbits; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*
chemical_list: D015415:Biomarkers; D000960:Hypolipidemic Agents; D014280:Triglycerides; D000255:Adenosine Triphosphate
keywords: Adenosine triphosphate; hyperlipidemia; triglyceride